Lumenis to Present Interim Safety and Efficacy Results of IPL with OPT™ for Treating Dry Eye at Major Ophthalmology Meeting

YOKNEAM, Israel--()--ASCRS Booth #2311-- Lumenis, Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, will present interim results of a multicenter prospective clinical trial designed to study the safety and efficacy of Optimal Pulse Technology (OPTTM), the next generation of Intense Pulse Light (IPL) technology, for treating Dry Eye Disease (DED). Data from the trial, being led by Steven J. Dell, MD, of Dell Laser Consultants in Austin, Texas, will be presented at a conference of anterior segment ophthalmologists being held May 6-10 in New Orleans, LA.

In the trial, 40 patients from 2 centers will receive 3 IPL with OPTTM treatments for DED caused by Meibomian Gland Dysfunction (MGD). Tear break-up time, SPEED questionnaire scores, tear osmolarity and additional endpoints will be measured at baseline and again after treatment.

“Dry Eye disease is known to cause visual symptoms, but the effect it has on patients’ quality of life is often underappreciated. Many of my patients with dry eye due to MGD report significant ocular discomfort that limits their ability to work, participate in hobbies or use computers, smartphones and tablets. For these reasons, it is important that we have effective and safe treatments that help patients resume normal activities without visual symptoms,” Dr. Dell said.

Sheila Barbarino, MD, of Dell Laser Consultants, will present interim results of 14 patients who finished all treatments and follow-ups.

“I am excited to present the data from our study,” Dr. Barbarino said. “More than 40 million Americans suffer from dry eye and several studies show that MGD plays a primary role in a majority of cases. The data from our study suggests that IPL with OPTTM could be an important addition to our armamentarium of treatments for this prevalent, life-altering disease.”

Lumenis M22 IPL with OPTTM is a clinically proven and US Food and Drug Administration (FDA)-cleared therapy for a wide range of skin conditions, including inflammatory disorders such as rosacea. More than a decade ago, Rolando Toyos, MD, of Toyos Clinic in Nashville, TN, observed that patients treated with IPL for skin conditions reported significant improvement in ocular symptoms and signs, in some cases including resolution of concomitant MGD. Studies show that over 85% of individuals with skin and eyelid inflammation also suffer from inflammatory ocular conditions, such as MGD, blepharitis and eyelid telangiectasia. IPL with OPTTM may selectively target abnormal blood vessels and remove a major source of inflammation from the skin and eyelids of these patients, providing symptomatic relief and addressing the underlying causative pathway of their ocular disease.

Lumenis OPTTM proprietary technology ensures the delivery of consistent and homogenous levels of energy during brief IPL pulses, thus eliminating unsafe energy spikes, increasing reproducibility and improving results with fewer treatment sessions while reducing the risk of skin damage.

Dr. Barbarino’s presentation will be held Sunday, May 08 at 8:22 AM in Room 209, New Orleans Ernest N. Morial Convention Center.

Lumenis will be located at Booth #2311.

About Lumenis, Ltd.

Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Our drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century. The world over, we bring Energy to Healthcare. For more information, visit: www.lumenis.com.

Contacts

Pascale Communications
Jessica Griffith, 610-618-0013
jessica@pascalecommunications.com

Contacts

Pascale Communications
Jessica Griffith, 610-618-0013
jessica@pascalecommunications.com